01:37 PM EDT, 10/23/2025 (MT Newswires) -- Zymeworks ( ZYME ) said Thursday that initial data showed early signs of anti-tumor activity in the phase 1 trial evaluating ZW191 in patients with advanced solid tumors, such as ovarian, endometrial and non-small cell lung cancer.

The objective response rate for gynecological cancer participants was 64% at doses of 6.4 mg/kg to 9.6 mg/kg, the company said. Among the 27 response-evaluable patients, the objective response rate was 53% at the same dose range, the company added.

Zymeworks ( ZYME ) said ZW191, an antibody-drug conjugate targeting a protein found in about 75% of high-grade serous ovarian carcinomas and roughly 70% of lung adenocarcinomas, also showed a "manageable" safety profile, with no serious treatment-related adverse events.

The company said the initial findings support further evaluation of ZW191, with dose optimization in ovarian cancer planned for Q4.

Price: 17.76, Change: +0.09, Percent Change: +0.51